<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399773</url>
  </required_header>
  <id_info>
    <org_study_id>9910</org_study_id>
    <secondary_id>NCI-2017-02205</secondary_id>
    <secondary_id>9910</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>P50HL110787</secondary_id>
    <nct_id>NCT03399773</nct_id>
  </id_info>
  <brief_title>Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes</brief_title>
  <official_title>Infusion of Off the Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (NLA101) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo
      expanded cord blood progenitor cells (NLA101) works in treating patients with blood cancer.
      Before the transplant, patients will receive chemotherapy (fludarabine, cyclophosphamide and
      in some cases thiotepa) and radiation therapy. Giving chemotherapy and total-body irradiation
      before a donor umbilical cord blood transplant helps stop the growth of cells in the bone
      marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop
      the patient's immune system from rejecting the donor's stem cells. When the healthy stem
      cells from a donor are infused into the patient they may help the patient's bone marrow make
      stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may
      also replace the patient's immune cells and help destroy any remaining cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Primary graft failure/rejection as defined by no neutrophil recovery by day 45 (regardless
      of donor chimerism) or autologous recovery (neutrophil recovery but &lt; 10% donor chimerism in
      blood and bone marrow [BM]) by day 45.

      SECONDARY OBJECTIVES:

      I. Examine the safety and toxicity of infusing NLA101.

      II. Neutrophil and platelet engraftment.

      III. Incidence of acute graft versus host disease (GVHD) at day 100 and chronic GVHD at 1
      year.

      IV. Non-relapse mortality at day 100 and 180.

      OUTLINE:

      Patients receive either regimen A or regimen B.

      REGIMEN A: Patients (18 through 45 years old) receive fludarabine intravenously (IV) over 30
      minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo total
      body irradiation (TBI) twice daily (BID) on days -4 to -1. Patients receive unmanipulated
      cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.

      REGIMEN B: Patients (18 through 65 years old) receive fludarabine IV over 30-60 minutes on
      days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, and thiotepa
      IV over 4 hours on days -5 and -4. Patients receive unmanipulated cord blood unit IV followed
      by NLA101 IV within the next 24 hours on day 0.

      After completion of study treatment, patients are followed up at 180 days, 1 year, and 2
      years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2018</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft failure</measure>
    <time_frame>Up to day 45 post-transplant</time_frame>
    <description>Primary graft failure/rejection as defined by no neutrophil recovery (regardless of donor chimerism) or autologous recovery (neutrophil recovery but &lt; 10% donor chimerism in blood and bone marrow [BM]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of acute graft versus host disease (GVHD)</measure>
    <time_frame>At day 100 post-transplant</time_frame>
    <description>Assessed using the Acute GVHD Grading Scale (reference: Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-8).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of chronic graft versus host disease (GVHD)</measure>
    <time_frame>Up to approximately 2 years post-transplant</time_frame>
    <description>Assessed using the Chronic GVHD Grading Scale (reference: Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Blood Marrow Transplant 2005; 11: 945-56).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutrophil engraftment</measure>
    <time_frame>Up to day 45 post-transplant</time_frame>
    <description>The day of neutrophil recovery will be the 1st day of 2 consecutive days of absolute neutrophil count at or above 500 after the 1st post-cord blood transplant nadir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet engraftment measured by the number of participants with a platelet count &gt; 20,000/Î¼l without subsequent transfusions for 7 days</measure>
    <time_frame>Up to day 100 post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to day 100 post-transplant</time_frame>
    <description>Toxicities will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>At day 100 post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>At 1 year post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Blasts Under 10 Percent of Bone Marrow Nucleated Cells</condition>
  <condition>Blasts Under 5 Percent of Bone Marrow Nucleated Cells</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Cytogenetic Abnormality</condition>
  <condition>High Risk Myelodysplastic Syndrome</condition>
  <condition>Myelodysplastic Syndrome With Excess Blasts</condition>
  <condition>Pancytopenia</condition>
  <condition>Refractory Anemia</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive either regimen A or regimen B.
REGIMEN A: Patients (18 through 45 years old) receive fludarabine IV over 30 minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.
REGIMEN B: Patients (18 through 65 years old) receive fludarabine IV over 30-60 minutes on days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, and thiotepa IV over 4 hours on days -5 and -4. Patients receive unmanipulated cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>1,1',1''-Phosphinothioylidynetrisaziridine</other_name>
    <other_name>Girostan</other_name>
    <other_name>N,N', N''-Triethylenethiophosphoramide</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Tio-tef</other_name>
    <other_name>Triethylene thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>Tris(1-aziridinyl)phosphine sulfide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Umbilical Cord Blood Transplantation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>Cord Blood Transplantation</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical Cord Blood-derived Hematopoietic CD34-positive Progenitor Cells</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, TBI, NLA101)</arm_group_label>
    <other_name>Ex Vivo-expanded Umbilical Cord Blood-derived Hematopoietic CD34-positive Progenitor Cells</other_name>
    <other_name>NiCord</other_name>
    <other_name>UCB-derived CD34+ HPCs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have hematologic malignancy that meets institutional eligibility
             requirements for cord blood transplant

          -  Malignancies included are:

               -  Acute leukemia, including Acute myeloid leukemia (AML), biphenotypic acute
                  leukemia or mixed-lineage leukemia, acute lymphoblastic leukemia (ALL); all
                  patients must be in complete response (CR) as defined by &lt; 5% blasts by
                  morphology/flow cytometry in a representative bone marrow sample with adequate
                  cellularity to assess remission status

               -  Myelodysplasia (MDS) International Prognostic Scoring System (IPSS) intermediate
                  (Int)-2 or high risk (i.e., RAEB, RAEBt) or refractory anemia with severe
                  pancytopenia or high risk cytogenetics; blasts must be &lt; 10% by a representative
                  bone marrow aspirate morphology

               -  Chronic Myeloid Leukemia excluding refractory blast crisis; to be eligible in
                  first chronic phase (CP1) patient must have failed or be intolerant to tyrosine
                  kinase inhibitor therapy

          -  High dose TBI regimen: 18 to =&lt; 45 years

          -  Intermediate intensity regimen: 18 =&lt; 65 years

          -  Patients 18 to =&lt; 45 years: Karnofsky (&gt;= 18 years old) &gt;= 70 or Eastern Cooperative
             Oncology Group (ECOG) 0-1

          -  Patients &gt; 45 to =&lt; 65 years: Karnofsky &gt;= 70 or ECOG 0-1 and non-age adjusted
             comorbidity index =&lt; 5

          -  Calculated creatinine clearance must be &gt; 60 mL and serum creatinine =&lt; 2 mg/dL

          -  Total serum bilirubin must be &lt; 3mg/dL unless the elevation is thought to be due to
             Gilbert's disease or hemolysis

          -  Transaminases must be &lt; 3 x the upper limit of normal per reference values of treating
             institution

          -  Carbon monoxide diffusing capability (DLCO) corrected &gt;= 60% normal (may not be on
             supplemental oxygen)

          -  Left ventricular ejection fraction &gt;= 50% OR

          -  Shortening fraction &gt; 26%

          -  Ability to understand and the willingness to sign a written informed consent form

          -  DONOR: Minimum requirement: The cord blood (CB) unit must be matched at a minimum at
             4/6 HLA-A, B antigens and DRB1 allele with the recipient; therefore, 0-2 mismatches at
             the A or B or DRB1 loci based on intermediate resolution at HLA-A, B and high
             resolution allele level typing at HLA- DRB1 are allowed

          -  DONOR: Institutional guidelines for HLA-match may be followed as long as the minimum
             criteria for HLA-matching as above are met

          -  DONOR: The CB unit selected for transplant must have a MINIMUM of 2.5 x 10^7 TNC/kg

          -  DONOR: The minimum recommended CD34/kg cell dose is 1.7 x 10^5 CD34/kg

          -  DONOR: A domestic backup unit must be identified and reserved prior to the start of
             the treatment plan for possible infusion in the unlikely event of poor post-thaw
             viability of the primary CB unit

        Exclusion Criteria:

          -  Uncontrolled viral or bacterial infection at the time of study enrollment

          -  Active or recent (prior 6 month) invasive fungal infection unless cleared by
             innovation and development (ID) consult

          -  History of human immunodeficiency virus (HIV) infection

          -  Pregnant or breastfeeding

          -  Prior allogeneic transplant

          -  Central nervous system (CNS) leukemic involvement not clearing with intrathecal
             chemotherapy; diagnostic lumbar puncture is to be performed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Milano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juliet N. Barker</last_name>
    </contact>
    <investigator>
      <last_name>Juliet N. Barker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Filippo Milano</last_name>
    </contact>
    <investigator>
      <last_name>Filippo Milano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2017</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

